Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A. Romaguera JE, et al. Among authors: hartig k. Cancer. 2018 Jun 15;124(12):2561-2569. doi: 10.1002/cncr.31361. Epub 2018 May 3. Cancer. 2018. PMID: 29723393 Free article. Clinical Trial.
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Romaguera JE, et al. Among authors: hartig k. Br J Haematol. 2010 Jul;150(2):200-8. doi: 10.1111/j.1365-2141.2010.08228.x. Epub 2010 May 26. Br J Haematol. 2010. PMID: 20528872 Free article. Review.
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez A, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Romaguera JE, et al. Among authors: hartig k. Br J Haematol. 2010 Oct;151(1):47-53. doi: 10.1111/j.1365-2141.2010.08315.x. Epub 2010 Aug 5. Br J Haematol. 2010. PMID: 20735402 Free article. Clinical Trial.
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Wang M, et al. Among authors: hartig k. Lancet Oncol. 2012 Jul;13(7):716-23. doi: 10.1016/S1470-2045(12)70200-0. Epub 2012 Jun 6. Lancet Oncol. 2012. PMID: 22677155 Clinical Trial.
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma.
Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Lee HJ, et al. Among authors: hartig k. Oncologist. 2017 May;22(5):549-553. doi: 10.1634/theoncologist.2016-0328. Epub 2017 Apr 13. Oncologist. 2017. PMID: 28408615 Free PMC article. Clinical Trial.
Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.
Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, Cai Q, Zhang R, McIntosh J, Wang R, Dang M, Dai E, Wang Y, Santos D, Badillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Zhou J, Kanagal-Shamanna R, Ok CY, Lee H, Steiner RE, Zhang J, Song X, Nair R, Ahmed S, Rodriquez A, Thirumurthi S, Jain P, Wagner-Bartak N, Hill H, Nomie K, Flowers C, Futreal A, Wang L, Wang M. Zhang S, et al. Among authors: hartig k. Nat Commun. 2021 May 17;12(1):2877. doi: 10.1038/s41467-021-22872-z. Nat Commun. 2021. PMID: 34001881 Free PMC article.
Author Correction: Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.
Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, Cai Q, Zhang R, McIntosh J, Wang R, Dang M, Dai E, Wang Y, Santos D, Badillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Zhou J, Kanagal-Shamanna R, Ok CY, Lee H, Steiner RE, Zhang J, Song X, Nair R, Ahmed S, Rodriquez A, Thirumurthi S, Jain P, Wagner-Bartak N, Hill H, Nomie K, Flowers C, Futreal A, Wang L, Wang M. Zhang S, et al. Among authors: hartig k. Nat Commun. 2024 Oct 7;15(1):8668. doi: 10.1038/s41467-024-52013-1. Nat Commun. 2024. PMID: 39375332 Free PMC article. No abstract available.
Laser-Induced Plasmas of Plutonium Dioxide in a Double-Walled Cell.
Villa-Aleman E, Kwapis EH, Foley BJ, Shehee TC, Dick DD, Darvin JR, Ajo HM, Hartig KC. Villa-Aleman E, et al. Among authors: hartig kc. Appl Spectrosc. 2024 Apr;78(4):412-422. doi: 10.1177/00037028241226977. Epub 2024 Feb 5. Appl Spectrosc. 2024. PMID: 38317274
31 results